Loss of p16INK4a abrogates the inhibition of cyclin‐dependent kinase 4/6 (CDK4/6)–cyclin D pathway, and then cooperates with hyperactivated RAS‐RAF to induce melanoma 98, 99, 100, 101. Here, CDKN2A is linked to melanoma.